Elena Tsantes

Parma, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

The impact of multiple sclerosis on social determinants of health: Results from the SocialMS study.

The impact of multiple sclerosis on social determinants of health: Results from the SocialMS study.

Journal: Multiple sclerosis and related disorders

Published: March 23, 2026

Abuse in individuals with multiple sclerosis: the SocialMS Italian study.

Abuse in individuals with multiple sclerosis: the SocialMS Italian study.

Journal: Multiple sclerosis and related disorders

Published: October 13, 2025

Ofatumumab Versus Intravenous Ocrelizumab after Sphingosine-1-Phosphate Receptor Modulators in Patients with Relapsing-Remitting Multiple Sclerosis: A Real-World Inverse Probability of Treatment Weighting Multicenter Study.

Ofatumumab Versus Intravenous Ocrelizumab after Sphingosine-1-Phosphate Receptor Modulators in Patients with Relapsing-Remitting Multiple Sclerosis: A Real-World Inverse Probability of Treatment Weighting Multicenter Study.

Journal: CNS drugs

Published: September 28, 2025

Sex differences in relapse-independent and relapse-associated disability progression in relapsing-remitting multiple sclerosis: a real-world inverse-probability weighted study.

Sex differences in relapse-independent and relapse-associated disability progression in relapsing-remitting multiple sclerosis: a real-world inverse-probability weighted study.

Journal: Therapeutic advances in neurological disorders

Published: June 10, 2025

Prevalence of 2-year "No evidence of disease activity" (NEDA-3 and NEDA-4) in relapsing-remitting multiple sclerosis. A real-world study.

Prevalence of 2-year "No evidence of disease activity" (NEDA-3 and NEDA-4) in relapsing-remitting multiple sclerosis. A real-world study.

Journal: Multiple sclerosis and related disorders

Published: August 10, 2023

Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic.

Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: August 10, 2022

Secondary cluster headache due to a contralateral demyelinating periaqueductal gray matter lesion.

Secondary cluster headache due to a contralateral demyelinating periaqueductal gray matter lesion.

Journal: Headache

Published: January 03, 2021

Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy.

Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy.

Journal: Neuroepidemiology

Published: November 02, 2020

Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing-remitting multiple sclerosis.

Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing-remitting multiple sclerosis.

Journal: European journal of neurology

Published: May 21, 2020

Copper deficiency-associated myelopathy in cryptogenic hyperzincemia: a case report.

Copper deficiency-associated myelopathy in cryptogenic hyperzincemia: a case report.

Journal: Acta bio-medica : Atenei Parmensis

Published: May 06, 2020

The contribution of enhancing lesions in monitoring multiple sclerosis treatment: is gadolinium always necessary?

The contribution of enhancing lesions in monitoring multiple sclerosis treatment: is gadolinium always necessary?

Journal: Journal of neurology

Published: April 10, 2020

Five- and seven-year prognostic value of new effectiveness measures (NEDA, MEDA and six-month delayed NEDA) in relapsing-remitting multiple sclerosis.

Five- and seven-year prognostic value of new effectiveness measures (NEDA, MEDA and six-month delayed NEDA) in relapsing-remitting multiple sclerosis.

Journal: Journal of the neurological sciences

Published: December 23, 2019

Showing 1-12 of 18

Last Updated: 09/26/2026